Evidence map›Paper›PMID 19602254›Full record

ArticleBMC cancer2009

Differences in regulation of tight junctions and cell morphology between VHL mutations from disease subtypes.

Valentina Bangiyeva, Ava Rosenbloom, Ashlynn E Alexander, Bella Isanova, Timothy Popko, Alan R Schoenfeld

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 27 citations in OpenAlex.

  1. Facile Synthesis of Homodimeric Protein Ligands.Chembiochem : a European journal of chemical biology · 2023
    Article
  2. Applications and Limitations of Oxime-Linked "Split PROTACs".Chembiochem : a European journal of chemical biology · 2022
    Article
  3. Article
  4. The Most CommonCancers · 2021
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Von Hippel-Lindau syndrome: molecular mechanisms of the disease.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2010
    Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Valentina BangiyevaDepartment of Biology, Adelphi University, Garden City, NY 11530-0701, USA. vbangiyeva@yahoo.com
Ava Rosenbloom
Ashlynn E Alexander
Bella Isanova
Timothy Popko
Alan R Schoenfeld
Adelphi University · US

Funding

Unraveling the roles of VHL and hypoxia-inducible factor in VHL phenotypesR15CA121992 · NCI · ADELPHI UNIVERSITY · PI SCHOENFELD, ALAN R · 2006 to 2011
$492k
NCI NIH HHS CA121992NCI NIH HHS R15 CA121992
6 · The paper itself

Abstract

backgroundIn von Hippel-Lindau (VHL) disease, germline mutations in the VHL tumor suppressor gene cause clear cell renal carcinomas, hemangioblastomas, and pheochromocytomas. The VHL gene product is part of an ubiquitin E3 ligase complex and hypoxia-inducible factor alpha (HIF-alpha) is a key substrate, although additional VHL functions have been described. A genotype-phenotype relationship exists in VHL disease such that specific VHL mutations elicit certain subsets of these tumors. Here, we examine VHL genotype-phenotype correlations at the cellular level, focusing on the regulation of tight junctions and cell morphology.

methodsWild-type and various mutant VHL proteins representing VHL disease subtypes were stably expressed in 3 VHL-negative renal carcinoma cell lines. Using these cell lines, the roles of various VHL-associated cellular functions in regulation of cell morphology were investigated.

resultsAs a whole, type 1 mutants varied greatly from type 2 mutants, demonstrating high levels of HIF-2alpha, cyclin D1 and alpha5 integrin, lower p27 levels, and a spindly, fibroblastic cellular appearance. Type 2 mutations demonstrated an epithelial morphology similar to wild-type VHL in the majority of the renal cell lines used. Knockdown of p27 in cells with wild-type VHL led to perturbations of both epithelial morphology and ZO-1 localization to tight junctions. ZO-1 localization correlated well with VHL disease subtypes, with greater mislocalization observed for genotypes associated with a higher risk of renal carcinoma. HIF-2alpha knockdown in 786-O partially restored ZO-1 localization, but did not restore an epithelial morphology.

conclusionVHL has both HIF-alpha dependent and HIF-alpha independent functions in regulating tight junctions and cell morphology that likely impact the clinical phenotypes seen in VHL disease.

Indexed as

Gene Expression RegulationMutationCarcinomaCell LineCycloheximideGenotypeHumansHypoxia-Inducible Factor 1, alpha SubunitKidney NeoplasmsModels, BiologicalPhenotypeProtein Synthesis InhibitorsTight JunctionsUbiquitinVon Hippel-Lindau Tumor Suppressor ProteinCycloheximideHypoxia-Inducible Factor 1, alpha SubunitProtein Synthesis InhibitorsUbiquitinVHL protein, humanVon Hippel-Lindau Tumor Suppressor Protein

Identifiers

PMID19602254
PMCPMC2722669
OpenAlexW1982882402

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.